| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines (NCT04143815) | Medy-Tox | 2019-05-20 |
| Rucaparib in Nonmetastatic prOstAte With BRCAness (NCT03533946) | University of Utah | 2019-05-20 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion (NCT03900715) | Celgene | 2019-05-20 |
| Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine (NCT05192265) | University of Ibadan | 2019-05-20 |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03745352) | National Cancer Institute (NCI) | 2019-05-20 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis (NCT03633396) | Vanda Pharmaceuticals | 2019-05-20 |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer (NCT03524261) | Fuda Cancer Hospital, Guangzhou | 2019-05-20 |
| A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (NCT03930953) | Celgene | 2019-05-20 |
| Ribociclib and Letrozole Treatment in Ovarian Cancer (NCT03673124) | Gynecologic Oncology Group | 2019-05-20 |
| Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation (NCT03908736) | University of New Mexico | 2019-05-19 |
| A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis (NCT04004325) | Forma Therapeutics, Inc. | 2019-05-17 |
| PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer (NCT05812326) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2019-05-17 |
| Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis (NCT03982797) | Biofabri, S.L | 2019-05-17 |
| BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage (NCT03737344) | Adrian Parry-Jones | 2019-05-17 |
| Her2-positive Lung Cancer Treated With Dedicated Drug (NCT03845270) | Intergroupe Francophone de Cancerologie Thoracique | 2019-05-17 |
| Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study) (NCT03865732) | Marinus Pharmaceuticals | 2019-05-17 |
| Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes (NCT03973827) | NextCell Pharma Ab | 2019-05-17 |
| Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer (NCT03958097) | The First Hospital of Jilin University | 2019-05-17 |
| Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (NCT03973333) | Immunocore Ltd | 2019-05-17 |
| A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis (NCT03822455) | AlgiPharma AS | 2019-05-16 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (NCT03430700) | University College, London | 2019-05-16 |
| Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease (NCT03867253) | Oryzon Genomics S.A. | 2019-05-16 |
| FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (NCT03723967) | Centre Leon Berard | 2019-05-16 |
| Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO) (NCT04460001) | Assiut University | 2019-05-16 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03745326) | National Cancer Institute (NCI) | 2019-05-16 |
| Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (NCT03946748) | Regeneron Pharmaceuticals | 2019-05-16 |
| BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence (NCT03861936) | Allergan | 2019-05-16 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (NCT03801525) | TG Therapeutics, Inc. | 2019-05-16 |
| Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT) (NCT03846505) | Medical University of South Carolina | 2019-05-16 |
| Simvastatin in Secondary Progressive Multiple Sclerosis (NCT03896217) | University College, London | 2019-05-16 |
| GB001 in Adult Participants With Chronic Rhinosinusitis (NCT03956862) | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | 2019-05-16 |
| Effects of Semaglutide in HIV-Associated Lipohypertrophy (NCT04019197) | Case Western Reserve University | 2019-05-16 |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (NCT03951831) | Mark Stein | 2019-05-16 |
| Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3) (NCT03912532) | NGM Biopharmaceuticals, Inc | 2019-05-16 |
| Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum (NCT03971643) | InflaRx GmbH | 2019-05-16 |
| Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline (NCT03968562) | State University of New York - Downstate Medical Center | 2019-05-15 |
| SRAM study_Postate Cancer (NCT03938649) | CCTU | 2019-05-15 |
| Topical Chamomile in Preventing Chemotherapy-induced Oral Mucositis (NCT04317183) | Hams Hamed Abdelrahman | 2019-05-15 |
| Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690 (NCT04046250) | Tosk, Inc. | 2019-05-15 |
| Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab (NCT03698461) | Asan Medical Center | 2019-05-15 |
| NADIM II: Neo-Adjuvant Immunotherapy (NCT03838159) | Fundación GECP | 2019-05-15 |
| The Bihormonal iLet Bionic Pancreas Feasibility Study (NCT03840278) | Massachusetts General Hospital | 2019-05-15 |
| Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (NCT03836066) | Fundación GECP | 2019-05-15 |
| Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer (NCT03972722) | Guangzhou Gloria Biosciences Co., Ltd. | 2019-05-15 |
| Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma (NCT03971461) | NYU Langone Health | 2019-05-15 |
| NISCI - Nogo Inhibition in Spinal Cord Injury (NCT03935321) | University of Zurich | 2019-05-15 |
| Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma (NCT03506139) | John M. Buatti | 2019-05-15 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038) | M.D. Anderson Cancer Center | 2019-05-15 |
| Smell Changes & Efficacy of Nasal Theophylline (NCT03990766) | Washington University School of Medicine | 2019-05-15 |
| A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (NCT03980002) | Institute of Hematology & Blood Diseases Hospital, China | 2019-05-15 |
| Abemaciclib in Patients with Oligodendroglioma (NCT03969706) | Stephen Bagley, MD, MSCE | 2019-05-15 |
| Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (NCT03886311) | Sarcoma Oncology Research Center, LLC | 2019-05-15 |
| Phase II Study of Regorafenib as Maintenance Therapy (NCT03793361) | Centre Oscar Lambret | 2019-05-15 |
| Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: (NCT03552068) | Hospices Civils de Lyon | 2019-05-15 |
| A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease (NCT03677648) | Reistone Biopharma Company Limited | 2019-05-14 |
| GEN1046 Safety Trial in Patients With Malignant Solid Tumors (NCT03917381) | Genmab | 2019-05-14 |
| Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (NCT03474133) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2019-05-14 |
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer (NCT03828799) | Institut du Cancer de Montpellier - Val d'Aurelle | 2019-05-14 |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome (NCT03503409) | Groupe Francophone des Myelodysplasies | 2019-05-14 |
| Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma (NCT03834623) | H. Lee Moffitt Cancer Center and Research Institute | 2019-05-14 |
| Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease (NCT03954236) | Memorial Sloan Kettering Cancer Center | 2019-05-14 |
| Disulfiram and Cisplatin in Refractory TGCTs. (NCT03950830) | National Cancer Institute, Slovakia | 2019-05-14 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124) | Immatics US, Inc. | 2019-05-14 |
| Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (NCT03913559) | St. Jude Children's Research Hospital | 2019-05-14 |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer (NCT04001569) | Seoul National University Bundang Hospital | 2019-05-14 |
| CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients (NCT03591380) | University of Wisconsin, Madison | 2019-05-14 |
| Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (NCT03773133) | Ipsen | 2019-05-14 |
| Treatment of Radiation and Cisplatin Induced Toxicities with Tempol (NCT03480971) | Matrix Biomed, Inc. | 2019-05-13 |
| A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH (NCT03933293) | Akeso | 2019-05-13 |
| A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (NCT03771898) | Shire | 2019-05-13 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382) | National Cancer Institute (NCI) | 2019-05-13 |
| A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib (NCT03823378) | AbbVie | 2019-05-13 |
| Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) (NCT03935204) | Xiamen University | 2019-05-13 |
| Cardiac Allograft Vasculopathy Inhibition With Alirocumab (NCT03537742) | Stanford University | 2019-05-13 |
| Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity (NCT03943095) | GlaxoSmithKline | 2019-05-13 |
| Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung (NCT03589547) | Brown University | 2019-05-13 |
| Extension Study to Study PQ-110-001 (NCT03140969) (NCT03913130) | Laboratoires Thea | 2019-05-13 |
| Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (NCT03903822) | Pfizer | 2019-05-13 |
| Modulation of Gut Microbiota by Rifaximin in PD Patients (NCT03958708) | Taipei Medical University Shuang Ho Hospital | 2019-05-13 |
| Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma (NCT03951571) | Fudan University | 2019-05-13 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (NCT03772353) | Fudan University | 2019-05-12 |
| Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery (NCT03770637) | Xeris Pharmaceuticals | 2019-05-10 |
| Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (NCT03627403) | University of Utah | 2019-05-10 |
| Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults (NCT03821623) | Douglas Seals | 2019-05-10 |
| Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer (NCT03926338) | Sun Yat-sen University | 2019-05-10 |
| Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes (NCT03762759) | Emory University | 2019-05-10 |
| Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) (NCT03943290) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2019-05-10 |
| Safety Study for Beta Thalassemia Subjects on PTG-300 (NCT04054921) | Protagonist Therapeutics, Inc. | 2019-05-10 |
| Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma (NCT03951597) | Shanghai Zhongshan Hospital | 2019-05-10 |
| CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer (NCT03721757) | The Clatterbridge Cancer Centre NHS Foundation Trust | 2019-05-10 |
| Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer (NCT03946969) | The First Affiliated Hospital with Nanjing Medical University | 2019-05-09 |
| IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (NCT03753659) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-05-09 |
| A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants (NCT03253263) | OHB Neonatology Ltd. | 2019-05-09 |
| Detection of miRNAs in HPA Axis Function in Healthy Subjects (NCT04066647) | Cedars-Sinai Medical Center | 2019-05-09 |
| A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine (NCT03922750) | Novo Nordisk A/S | 2019-05-09 |
| Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma (NCT03921021) | Weill Medical College of Cornell University | 2019-05-09 |
| Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (NCT03620643) | Royal Marsden NHS Foundation Trust | 2019-05-09 |
| LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study) (NCT04041609) | Lyra Therapeutics | 2019-05-09 |